Imugene Reports Third Response in BTKi Cohort of azer-cel Trial
Key points
- Third response achieved in concurrent BTKi cohort of azer-cel Phase 1b study
- Second FL patient in the cohort reports a partial response
- Both FL patients in the cohort responded to treatment with azer-cel and BTKi
Full summary
Imugene Limited (ASX: IMU) reports additional patient data from the concurrent BTK inhibitor (BTKi) cohort of its ongoing azer-cel (azercabtagene zapreleucel) Phase 1b clinical trial. The third response in the cohort was achieved by a second Follicular Lymphoma (FL) patient, who had previously progressed on BTKi therapy. Both FL patients in the concurrent BTKi cohort have demonstrated a response to treatment with azer-cel and a BTKi. The trial aims to evaluate whether concurrent dosing of azer-cel with a BTKi can restore or enhance therapeutic activity in patients with B-cell malignancies who have developed resistance to BTKi therapy.
Summary generated by a large language model. Please interpret with care.